CSPG4 and PTK2

  • Number of citations of the paper that reports this interaction (PMID 10587647)
  • 45
  • Data Source:
  • HPRD (in vitro, in vivo)

CSPG4

PTK2

Gene Name chondroitin sulfate proteoglycan 4 protein tyrosine kinase 2
Image No pdb structure
Gene Ontology Annotations Cellular Component
Molecular Function
Biological Process
Pathways
Drugs
Diseases
GWAS
  • Response to interferon beta therapy ( 21502966)
Protein-Protein Interactions 9 interactors: ATF7IP BCAR1 C1QA CDC42 GRIP1 GRIP2 MPDZ PTK2 TNK2 104 interactors: ACTN1 APP ARHGAP26 ASAP1 ATG12 BBS10 BCAR1 BIN1 BMX CCR5 CD47 CD79B CIB1 CRK CSK CSPG4 CXCR4 DCC DDX39A DEF6 DLGAP3 DNM2 EEF1G EFS EGFR EPHA2 EPHB2 EPS8L2 ERBB2 ERBB3 EZR F13A1 FBP1 FGR FLT1 FLT4 FYN GIT1 GRB2 GRB7 GSK3B GZMB HES1 IGHM INSR IRS1 ITGAV ITGB1 ITGB2 ITGB3 ITGB4 ITGB5 JAK2 KCNMA1 LCK LPXN LYN MAPK8IP3 MDM2 MICAL1 NACAD NASP NCK1 NCK2 NEDD8 NEDD9 NEO1 PDGFRB PIAS1 PIK3R1 PKD1 PLCG1 PPP1CB PTK2B PTPN11 PTPN12 PTPRH PXN RAC1 RB1CC1 RET RIPK1 ROCK1 SAE1 SELE SHC1 SOCS2 SOCS3 SORBS1 SRC SRPK1 STAT1 SYK TGFB1I1 TLN1 TNFRSF1A TNS1 TP53 TRIO TRIP6 TSC2 VCL YES1 ZNF331
Entrez ID 1464 5747
HPRD ID 03105 02859
Ensembl ID ENSG00000173546 ENSG00000169398
Uniprot IDs Q6UVK1 E7ESA6 Q05397 Q59GM6 Q658W2
PDB IDs 1K04 1K05 1MP8 1OW6 1OW7 1OW8 2ETM 2IJM 2RA7 3B71 3BZ3 3PXK 3S9O 4EBV 4EBW 4GU6 4GU9 4I4E 4I4F 4K8A 4K9Y 4KAB 4KAO
Enriched GO Terms of Interacting Partners?
Tagcloud ?
avenues  breakthrough  checkpoint  constituted  counteract  ctla4  employ  helped  immunomodulatory  immunotherapies  immunotherapy  interface  l1  lethal  mcsp  melanoma  modalities  perhaps  promise  recognised  recognising  redirect  restrict  spread  standing  subsets  tumour  unexplored  vasculature 
acta  biochem  brindle  critchley  davies  fefpppptde  flexneri  icsa  immunofluoresence  microinjected  microinjection  nonmuscle  oligoproline  pdfpppppdl  profilin  reorganizes  rocket  sasakawa  shigella  submicromolar  suzuki  trailing  unmasked  unmasking  unmasks  usurping  vasp  vinc  vinculin 
Tagcloud (Difference) ?
avenues  breakthrough  checkpoint  constituted  counteract  ctla4  employ  helped  immunomodulatory  immunotherapies  immunotherapy  interface  l1  lethal  mcsp  melanoma  modalities  perhaps  promise  recognised  recognising  redirect  restrict  spread  standing  subsets  tumour  unexplored  vasculature 
acta  biochem  brindle  critchley  davies  fefpppptde  flexneri  icsa  immunofluoresence  microinjected  microinjection  nonmuscle  oligoproline  pdfpppppdl  profilin  reorganizes  rocket  sasakawa  shigella  submicromolar  suzuki  trailing  unmasked  unmasking  unmasks  usurping  vasp  vinc  vinculin 
Tagcloud (Intersection) ?